Ugur Gunaydin's lobbying: the registrations they file and every meeting they've reported since November 2021.
← LobbyingRegistrant (responsible officer)
General Manager, Canada
For companies and organizations, the most senior paid officer files the registration and the monthly reports, whoever attended the meeting.
Communicating with government officials about the Food and Drugs Act, including about (i) the approval framework for drug products, such as subsequent entry biologics (also known as biosimilars), (ii) export and cross-border trade restrictions for drug products, (iii) data exclusivity for drug products, (iv) approvals (and subsequent reviews) for new drug submissions, and (v) post-market surveillance of drug products.
Communicating, in general, with government officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy.
Communicating with government officials about the Food and Drugs Act, including about (i) the approval framework for drug products, such as subsequent entry biologics (also known as biosimilars), (ii) export and cross-border trade restrictions for drug products, (iii) data exclusivity for drug products, (iv) approvals (and subsequent reviews) for new drug submissions, and (v) post-market surveillance of drug products.
Communicating with government officials about improved health outcomes, including, but not limited to (i) expanding equitable access to innovative therapies, diagnostics and vaccines, (ii) promoting pricing reform, (iii) enhancing health security, including via the Health Emergency Readiness Canada ("HERC") Agency and (iv) promoting regulatory efficiency, including through regulatory modernization.
Communicating with government officials about the implementation and expansion of the national pharmacare program, including as it relates to the Pharmacare Act, S.C. 2024, c. 24.
Communicating with government officials about international trade, more specifically tariffs and non-tariff trade barriers affecting the life sciences and biopharmaceutical sectors.
Communicating with government officials about the pan-Canadian Health Data Strategy, more specifically about health data foundations.
Communicating with government officials about the implementation and expansion of the national pharmacare program, including as it relates to the Pharmacare Act, S.C. 2024, c. 24.
Communicating with government officials about the Food and Drugs Act, including about (i) the approval framework for drug products, such as subsequent entry biologics (also known as biosimilars), (ii) export and cross-border trade restrictions for drug products, (iii) data exclusivity for drug products, (iv) approvals (and subsequent reviews) for new drug submissions, and (v) post-market surveillance of drug products.
Communicating, in general, with government officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy.
Communicating with government officials about the Food and Drugs Act, including about (i) the approval framework for drug products, such as subsequent entry biologics (also known as biosimilars), (ii) export and cross-border trade restrictions for drug products, (iii) data exclusivity for drug products, (iv) approvals (and subsequent reviews) for new drug submissions, and (v) post-market surveillance of drug products.
Communicating, in general, with government officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy.
Communicating with government officials about the implementation and expansion of the national pharmacare program, including as it relates to the Pharmacare Act, S.C. 2024, c. 24.
Communicating with government officials about international trade, more specifically tariffs and non-tariff trade barriers affecting the life sciences and biopharmaceutical sectors.
Communicating with government officials about the implementation and expansion of the national pharmacare program, including as it relates to the Pharmacare Act, S.C. 2024, c. 24.
Communicating, in general, with government officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy.
Communicating with government officials about international trade, more specifically tariffs and non-tariff trade barriers affecting the life sciences and biopharmaceutical sectors.
Communicating with government officials about the implementation and expansion of the national pharmacare program, including as it relates to the Pharmacare Act, S.C. 2024, c. 24.
Communicating, in general, with government officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy.
Communicating with government officials about international trade, more specifically tariffs and non-tariff trade barriers affecting the life sciences and biopharmaceutical sectors.
Communicating with government officials about the implementation and expansion of the national pharmacare program, including as it relates to the Pharmacare Act, S.C. 2024, c. 24.
Communicating, in general, with government officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy.
Communicating with government officials about the Food and Drugs Act, including about (i) the approval framework for drug products, such as subsequent entry biologics (also known as biosimilars), (ii) export and cross-border trade restrictions for drug products, (iii) data exclusivity for drug products, (iv) approvals (and subsequent reviews) for new drug submissions, and (v) post-market surveillance of drug products.
Communicating with government officials about the implementation and expansion of the national pharmacare program, including as it relates to the Pharmacare Act, S.C. 2024, c. 24.
Communicating, in general, with government officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy.
Communicating, in general, with government officials about research, development and innovation in Canada's biomedical and biotechnology sector.
Communicating with government officials about the pan-Canadian Health Data Strategy, more specifically about health data foundations.
Communicating with government officials about expanding equitable access to innovative therapies, diagnostics and vaccines.
Communicating with government officials about a national pharmaceutical strategy, more specifically as it relates to (i) enhanced access to orphan drugs and (i) incentives for the development of rare disorder treatments.
Communicating with government officials about expanding equitable access to innovative therapies, diagnostics and vaccines.
Communicating with government officials about a national pharmaceutical strategy, more specifically as it relates to (i) enhanced access to orphan drugs and (i) incentives for the development of rare disorder treatments.
Health
Health
Health
Health
Health
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.